Email this article New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
- Authors: Poddubnaya I.V.1, Ptushkin V.V.2,3, Belousova I.E.4,5, Gorenkova L.G.6, Kaplanov K.D.7, Karamova A.E.8, Kovrigina A.M.9,10, Kolomeitsev O.A.11, Konstantinova T.S.12, Kokhan M.M.13, Pospelova T.I.14
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- City Clinical Hospital named after S.P. Botkin, Moscow Department of Health
- Moscow City Hematology Center
- S.M. Kirov Military Medical Academy
- Saint Petersburg Medical and Social Institute
- National Research Center for Hematology, Department of Intensive High-Dose Chemotherapy with Round-the-Clock and Day Hospital (IVHT with CS and DS)
- Volgograd Regional Clinical Oncology Center
- Federal State Budgetary Institution “State Scientific Center of Dermatovenerology and Cosmetology” of the Ministry of Health of Russia
- National Medical Research Center of Hematology, Ministry of Health of Russia
- Institute for Advanced Studies
- FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia
- Sverdlovsk Regional Clinical Hospital No. 1
- Ural Research Institute of Dermatovenerology and Immunopathology
- Novosibirsk State Medical University
- Issue: Vol 22, No 2 (2020)
- Pages: 79-81
- Section: Conference Proceedings
- URL: https://bakhtiniada.ru/1815-1434/article/view/34929
- DOI: https://doi.org/10.26442/18151434.2020.2.200205
- ID: 34929
Cite item
Full Text
Abstract
Relevance. Cutaneous T-cell lymphomas (CTCL) are not common diseases which are associated with a decrease in quality of life. Currently available systemic therapy rarely provides a stable and long-termed response. In Russia, current CTCL therapy is a big issue due to the limited access to modern targeted therapy, an absence of a National CTCL registry, and the difficulties in morphological diagnosis of these rare diseases. Since June 17, 2019, a new indication of brentuximab vedotin as a new treatment option for patients with CD30+ CTCL after at least one line of previous systemic therapy was registered. Brentuximab vedotin is a conjugate of a CD30 directed monoclonal antibody and an antitumor agent. Brentuximab vedotin is a CD30-directed monoclonal antibody conjugated to an antitumor agent.
Aim. To identify the unresolved issues of current clinical practice and to adapt available approaches to the treatment and diagnosis of CD30 + CTCL given new therapeutic opportunities.
Results. The available approaches to the systemic CTCL therapy in Russia routine clinical practice have been discussed, the unresolved issues of therapy and diagnosis have been identified, the routing of patients with CD30 + CTCL in Russia has been discussed, the importance of CD30 testing has been established, the profiles of patients with CTCL for treatment with brentuximab vedotin have been determined.
Full Text
##article.viewOnOriginalSite##About the authors
Irina V. Poddubnaya
Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: ivprectorat@inbox.ru
ORCID iD: 0000-0002-0995-1801
D. Sci. (Med.), Prof., Acad. RAS
Russian Federation, MoscowVadim V. Ptushkin
City Clinical Hospital named after S.P. Botkin, Moscow Department of Health; Moscow City Hematology Center
Email: or@hpmp.ru
Doctor of Medical Sciences, Professor
Russian Federation, MoscowIrena E. Belousova
S.M. Kirov Military Medical Academy; Saint Petersburg Medical and Social Institute
Email: irena.belousova@mail.ru
D. Sci. (Med.), Prof.
Saint PetersburgL. G. Gorenkova
National Research Center for Hematology, Department of Intensive High-Dose Chemotherapy with Round-the-Clock and Day Hospital (IVHT with CS and DS)
Email: or@hpmp.ru
ORCID iD: 0000-0002-3967-9183
врач-гематолог отд. ИВХТ с КС и ДС
Russian Federation, MoscowKamil D. Kaplanov
Volgograd Regional Clinical Oncology Center
Email: or@hpmp.ru
Candidate of Medical Sciences
Russian Federation, VolgogradA. E. Karamova
Federal State Budgetary Institution “State Scientific Center of Dermatovenerology and Cosmetology” of the Ministry of Health of Russia
Email: or@hpmp.ru
Cand. med. sciences, dermatologist, head. Dep. dermatology
Russian Federation, MoscowAlla M. Kovrigina
National Medical Research Center of Hematology, Ministry of Health of Russia; Institute for Advanced Studies
Email: or@hpmp.ru
Dr. med. sciences, pathologist, prof. cafe pathological anatomy, cytology and molecular pathology; Head pathoanatomical department; Member of the Presidium of the Russian Society of Pathologists, Member of the Board of the Russian Professional Society of Oncohematologists, Member of the National Hematology Society
Russian Federation, MoscowO. A. Kolomeitsev
FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia
Email: or@hpmp.ru
Oncologist, Scientific Advisory Department, Clinical Oncology Research Institute N.N. Trapeznikova
Russian Federation, MoscowT. S. Konstantinova
Sverdlovsk Regional Clinical Hospital No. 1
Email: or@hpmp.ru
Cand. med. sciences, head. Department of Hematology, hematologist of the highest category, chapters. Freelance hematologist of the Ural Federal District and the Ministry of Health of the Sverdlovsk Region
Russian Federation, YekaterinburgMuza M. Kokhan
Ural Research Institute of Dermatovenerology and Immunopathology
Email: or@hpmp.ru
Dr. med. sciences, prof., head. Scientific Clinical Dep. Dermatology, Honored Doctor of the Russian Federation
Russian Federation, YekaterinburgTatyana I. Pospelova
Novosibirsk State Medical University
Email: or@hpmp.ru
Dr. med. sciences, professor, hematologist, head. cafe therapy, hematology and transfusiology, hands. City Hematology Center
Russian Federation, NovosibirskReferences
- Инструкция по медицинскому применению лекарственного препарата Адцетрис® (РУ № ЛП-003476 от 26.02.2016), изменение №4 от 17.06.2019. [Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Adtsetris® (RU № LP-003476 ot 26.02.2016), izmenenie №4 ot 17.06.2019 (in Russian).]
- Prince HM, Kim YH, Horwitzet SM et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390: 555–66.
- Scarisbrick J, Horwitz S, Dummer R et al. Final ALCANZA results: brentuximab vedotin versus physician’s choice in previously treated CD30-positive cutaneous T-cell lymphoma (Mycosis fungoides or primary cutaneous anaplastic large cell lymphoma. Abstract V-05. 4 WCCL, 12-14.
- Клинические рекомендации МЗ по грибовидному микозу. http://cr.rosminzdrav.ru/#!/recomend/859 [Klinicheskie rekomendatsii MZ po gribovidnomu mikozu. http://cr.rosminzdrav.ru/#!/recomend/859 (in Russian).]
- Клинические рекомендации МЗ по синдрому Сезари. http://cr.rosminzdrav.ru/#!/recomend/991 [Klinicheskie rekomendatsii MZ po sindromu Sezari. http://cr.rosminzdrav.ru/#!/recomend/991 (in Russian).]
- Duvic M, Tetzlaff MT, Gangar P. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 2015; 33 (32): 3759–65. doi: 10.1200/JCO.2014.60.3787
- NCCN Clinical Practice Guidelines. Primary cutaneous lymphomas V.2-2020 https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf
- Willemze R, Hodak E., Zinzani PL et al. Primary Cutaneous Lymphomas: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29 (Suppl. 4): iv30–iv40.
Supplementary files
